Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma
Cells · 16.04.2026 · 15 (8) · 706
DOI: 10.3390/cells15080706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 16.04.2026. Verfasst von Michelle Lightfoot und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NYU Langone Health/Perlmutter Cancer Center, New York, NY 10016, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Extracellular Vesicles, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
Background
High-grade serous ovarian carcinoma (HGSOC) is the most common and lethal subtype of epithelial ovarian cancer and is frequently diagnosed at advanced stages. Because currently available blood-based biomarkers have limited performance in early-stage disease, there is a need to identify circulating biomarker candidates associated with early-stage HGSOC. In this retrospective multi-institutional case–control study, we evaluated whether serum extracellular vesicle (EV)-associated protein signatures distinguish early-stage HGSOC from healthy controls.
Methods
Serum samples (n = 252) were obtained retrospectively from multiple institutions and included healthy controls and patients with early- and advanced-stage HGSOC. EV-associated proteins were profiled using liquid chromatography–tandem mass spectrometry (LC–MS/MS) and proximity extension assay (PEA) to identify candidate proteins enriched in early-stage HGSOC. Selected candidates were evaluated by enzyme-linked immunosorbent assay (ELISA), and tissue-level expression was examined in early-stage HGSOC specimens. A multimarker combination model was generated using a smoothed empirical estimate of hyper-volume under the manifold (SHUM) approach and internally assessed by leave-one-out cross-validation.
Results
Ten EV-associated serum proteins were prioritized on the basis of differential expression and fold change and were confirmed to be expressed in early-stage HGSOC tissues. In ELISA-based analyses, the combined 10-protein EV panel distinguished early-stage HGSOC from healthy controls with an area under the curve (AUC) of 0.99 in the study dataset, whereas MUC16 (CA-125) showed substantially lower performance in this comparison. The SHUM-based model yielded a true-positive rate of 0.971, a false-positive rate of 0.057, and a Matthews correlation coefficient of 0.915 in the analyzed cohort. Several candidate proteins were differentially enriched in EV fractions but not in matched whole serum.
Conclusions
Serum EV-associated proteins are altered in early-stage HGSOC and define a multi-protein signature associated with this disease state in a retrospective case–control setting. These findings support further evaluation of EV-based biomarker candidates in clinically representative and prospectively collected cohorts that include benign gynecologic conditions, symptomatic patients, and pre-diagnostic samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NYU Langone Health/Perlmutter Cancer Center, New York, NY 10016, USA.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
- Department of Surgery, Virginia Commonwealth University School of Medicine, 1200 E Broad St., Richmond, VA 23298, USA.
- Department of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.
ORCID-Profile: Michelle Lightfoot, Karuppaiyah Selvendiran
Förderung
- Congressionally Directed Medical Research Programs
Zitieren
APA
Lightfoot, M., Dorayappan, K. D. P., Vudatha, V., Chakrapani, L. N., Das, P., Yu, L., Hisey, C., Sakaue, T., Muthusamy, T., Panneerselvam, P., Backes, F., Cosgrove, C., Hansford, D., Cohn, D. E., O'Malley, D. M., Gogna, R., & Selvendiran, K. (2026). Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma. Cells, 15(8), 706. https://doi.org/10.3390/cells15080706
Vancouver
Lightfoot M, Dorayappan KDP, Vudatha V, Chakrapani LN, Das P, Yu L, et al. Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma. Cells. 2026;15(8):706. doi:10.3390/cells15080706
BibTeX
@article{Lightfoot2026,
author = {Lightfoot, Michelle and Dorayappan, Kalpana Deepa Priya and Vudatha, Vignesh and Chakrapani, Lakshmi Narasimhan and Das, Priyam and Yu, Lianbo and Hisey, Colin and Sakaue, Takahiko and Muthusamy, Thangavel and Panneerselvam, Parthiban and Backes, Floor and Cosgrove, Casey and Hansford, Derek and Cohn, David E and O'Malley, David M and Gogna, Rajan and Selvendiran, Karuppaiyah},
title = {Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma},
journal = {Cells},
year = {2026},
volume = {15},
number = {8},
pages = {706},
doi = {10.3390/cells15080706}
}
EUVIMED